MarginsXMarginsX
Home › Markets › Health Care › GSK

GSK plc (GSK)

GSK trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$50.41
-0.08% on the day
Market cap
$102.0B
Large cap
Revenue · 2025
$43.2B
+4.1% on 2024
Net income · 2025
$7.6B
17.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1131399/000113139926000004/0001131399-26-000004-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2025-12-31. Converted from GBP at 0.7561 per USD (today's ECB or Federal Reserve reference rate).

Profile

FieldValue
TickerGSK on NYSE
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited Kingdom
IPO year2022
SEC CIK0001131399
SEC industry codePharmaceutical Preparations
Incorporated inUnited Kingdom

Financials · 2025

LineValue
Revenue$43.2B
Net income$7.6B
Operating income$10.5B
Net margin17.5%
Operating margin24.3%
Revenue growth+4.1%
Cash$4.5B
Total assets$80.8B
P/E (computed)13.5×
P/S (computed)2.4×

Reported in GBP; shown in US dollars.

Warning signs

Cash runway
Cash-flow positive
3.4B GBP cash at December 31, 2025
Share count, 1 year
0.0%
2024-12-31 to 2025-12-31 · +0.1% over 3 years
Going-concern doubt
No
20-F filed March 6, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-03-06
Cash and burn3.4B GBP cash; operating cash flow 1.9B GBP a quarter.Report 2025-12-31
Shares outstanding2,157,722,513 (2025-12-31); 2,157,151,867 a year earlier; 2,155,671,671 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
Delisting25-NSE filed25-NSE 2025-05-15
AuditorDeloitte LLP, London, United KingdomPCAOB Form AP 2026-03-30
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
32.7B GBP5.7B GBP7.7B GBP3.4B GBP14.5B GBP32.7B GBP20-F 2026-03-06
FY 2024
2024-12-31
31.4B GBP2.6B GBP6.6B GBP3.9B GBP13.1B GBP31.4B GBP20-F 2026-03-06
FY 2023
2023-12-31
30.3B GBP4.9B GBP6.8B GBP2.9B GBP15.0B GBP30.3B GBP20-F 2025-03-03
FY 2022
2022-12-31
29.3B GBP15.0B GBP7.4B GBP3.7B GBP17.2B GBP29.3B GBP20-F 2024-03-05
FY 2021
2021-12-31
24.7B GBP4.4B GBP8.0B GBP4.3B GBP19.8B GBP24.7B GBP20-F 2024-03-05
FY 2020
2020-12-31
24.4B GBP5.7B GBP8.4B GBP6.3B GBP20.8B GBP24.4B GBP20-F 2023-03-10
FY 2019
2019-12-31
33.8B GBP4.6B GBP8.0B GBP4.7B GBP25.2B GBP33.8B GBP20-F 2022-03-08
FY 2018
2018-12-31
30.8B GBP3.6B GBP8.4B GBP3.9B GBP21.6B GBP30.8B GBP20-F 2021-03-12

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in GBP.

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B22026-09-10
Latest annual report20-F2026-03-06
Latest quarterly / interim
BEXSERO BOOSTER RECEIVES POSITIVE CHMP OPINION
6-K2026-11-13

Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+0.2%
1 month+9.0%
3 months0.0%
Year to date+2.9%
1 year+4.8%
From 52-week high-17.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
REGNRegeneron Pharmaceuticals Inc.$952.40-0.32%$98.5B
SNYSanofi ADS$48.39+0.04%$118.0B
BMYBristol-Myers Squibb Company$62.93-0.79%$128.6B
VRTXVertex Pharmaceuticals Incorporated$537.79-0.15%$136.4B
TAKTakeda Pharmaceutical Company Limited$21.59+0.75%$68.2B
PFEPfizer Inc.$28.86-0.10%$164.5B
NVONovo Nordisk A/S$41.60-0.07%$184.2B
ABTAbbott Laboratories$107.45-0.99%$186.1B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier